Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IDWeek 2014: HIV Care Cascade at Kaiser Permanente Varies by Sex and Age

Though there has been improving performance of healthcare delivery at each point of the HIV care cascade, from linkage to care through viral suppression, "success varies significantly by age and gender, even in an integrated care system with equal access to care,” Michael Horberg of the Mid-Atlantic Permanente Research Institute reported yesterday at IDWeek 2014 in Philadelphia.

alt

Read more:

Second Potentially Cured Baby Has HIV Relapse Soon After Stopping Treatment

An Italian child who started antiretroviral treatment soon after birth and had undetectable plasma viral load, no apparent HIV DNA, and tested HIV antibody negative nevertheless experienced viral rebound shortly after a treatment interruption, once again disappointing hopes for a cure, researchers reported in the October 4 edition of The Lancet.

alt

Read more:

FDA Approves Elvitegravir and Cobicistat Booster as Stand-alone Drugs

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences next-generation HIV integrase inhibitor elvitegravir (brand name Viteka) and pharmacoenhancer cobicistat (Tybost) as stand-alone agents to be used in combination antiretroviral therapy. The 2 drugs were already available as part of the Stribild single-tablet regimen.

alt

Read more:

USCA 2014: U.S. Conference on AIDS Underway in San Diego

The 18th annual U.S. Conference on AIDS, sponsored by the National Minority AIDS Council, is taking place this week in San Diego. While other conferences focus on new data about antiretroviral therapy and biomedical prevention, USCA emphasizes the social, economic, and cultural aspects of HIV/AIDS.

alt

Read more:

Tenofovir Alafenamide Pill Matches Stribild, Gilead Will Seek Approval Soon

A new single-tablet regimen containing tenofovir alafenamide (TAF), elvitegravir, cobicistat, and emtricitabine worked as well as Stribild at 48 weeks in a pair of Phase 3 trials, but had less detrimental effects on the kidneys and bones, Gilead Sciences announced this week. These findings set the stage for evaluation by the U.S. Food and Drug Administration and European regulators.

alt

Read more:

Monkey Transplant Study Rules Out Possible HIV Cure Mechanism

Macaque monkeys that received transplants of their own stem cells after undergoing intensive radiation that killed off their existing SHIV-infected immune cells experienced viral rebound soon after stopping antiretroviral drugs, indicating that pre-transplant "conditioning" was not solely responsible for the only known case of a person cured of HIV.

alt

Read more:

ICAAC 2014: Stribild Works Well Regardless of Age, Sex, or Race/Ethnicity

The elvitegravir-based Stribild single-tablet regimen demonstrated good long-term efficacy and tolerability -- including fewer neuropsychiatric side effects than Atripla -- with consistent results across demographic subgroups, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC. Other studies showed that Stribild is a good option for black patients either initiating or switching antiretroviral therapy (ART).

alt

Read more: